The Role of Transplants in Patients With ALL

Video

Mark R. Litzow, MD, chair, ECOG-ACRIN Leukemia Committee, professor of medicine, Division of Hematology, Mayo Clinic, discusses the role of transplant in patients with acute lymphoblastic leukemia (ALL).

Mark R. Litzow, MD, chair, ECOG-ACRIN Leukemia Committee, professor of medicine, Division of Hematology, Mayo Clinic, discusses the role of transplant in patients with acute lymphoblastic leukemia (ALL).

Clinical Pearls:

  • The advent of pediatric-intensive chemotherapy regimens has demonstrated improved outcomes in younger patients compared to traditional chemotherapy regimens
  • Benefit has also been seen in patients up to 40-45 years old, but patients older than 40-45 years did not tolerate the pediatric-intensive chemotherapy regimens as well due to complications and treatment-related mortality
  • Due to these results, younger patients may not need transplants in first remission but younger patients with high-risk features, such as high white blood cell count or adverse cytogenetics, may still benefit from transplant
  • Outcomes are worse in older patients who undergo chemotherapy treatment, but reduced-intensity conditioning transplant regimens are in development and have demonstrated encouraging results in older patients
Related Videos
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Related Content